Subscribe

LSPN Fall North America 2024

LSPN Fall 2024 took place on October 15-16 in San Francisco, gathering an unrivalled assembly of in-house patent counsel, intellectual property professionals, and industry leaders from pharmaceutical and biotechnology companies. The event offered a unique opportunity to explore critical developments in the life sciences sector and provided attendees with actionable insights into patent strategies, key legal decisions, and the broader political landscape impacting innovation.

Speakers represented some of the biggest names in life sciences and intellectual property, including Acuitas Therapeutics, Thermo Fisher Scientific, 10x Genomics, Gilead Sciences, Pfizer, Bristol Myers Squibb, Illumina, Mammoth Biosciences, IGM Biosciences, DLA Piper, Morgan Lewis, Mintz, Nutcracker Therapeutics, and many more.

WATCH: Beyond Patents-The evolving role of IP lawyers in life sciences
In an incredibly competitive and complex landscape, intellectual property is a critical asset for pharmaceutical and biotech companies.


WATCH: The new EU Clinical Trials Regulation – IP Considerations
25 December 2024
WATCH: What we have learned so far and other thoughts on the new European patent litigation system
24 December 2024
WATCH: The Unified Patent Court from the Frontline
24 December 2024
WATCH: European IP landscape
22 December 2024
WATCH: Jurisdictional overreach of foreign courts in patent disputes
22 December 2024
WATCH: Intersectionality of Intellectual Property with Licensing and Commercialization
19 December 2024


Americas
WATCH: AI and machine learning in drug discovery - patenting AI-generated inventions
Machine learning can be an invaluable tool in drug discovery for target identification, compound screening, and predictive modeling. The use of AI can accelerate drug discovery timelines, reduce costs and enhance therapeutic outcomes.
Americas
WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?
The patent landscape for biologics, biosimilars, and advanced therapeutic antibodies is undergoing rapid change, presenting both opportunities and challenges for innovators and manufacturers. This panel will explore current issues and strategies in this dynamic field.
Americas
WATCH: Beyond the obvious: novelty, non-obviousness, and the inventive step in polymorph patents and beyond
In the world of intellectual property, securing patents for innovative ideas rests heavily on the criteria of novelty, non-obviousness, and the inventive step.
Americas
WATCH: Strategies for success: patent drafting and application
Join us for a master class in patent drafting for successful applications to the USPTO. Our panel of experts will share invaluable insights into their best practices for success in patent drafting and application.
Americas
WATCH: Essential considerations: patenting and clinical trials
There is an intricate intersection between patenting and clinical trials within the dynamic IP landscape in the life sciences industries. Safeguarding your innovation throughout the research process is critical, necessitating a careful balance between the need to file and when to file, explain speakers from IGM Biosciences, IP Recor Medical, and Sanaria Inc.
Americas
WATCH: Navigating enablement and written description requirement standards in the USPTO
On January 10 this year, the director of the USPTO issued new guidelines on enablement under 35 U.S.C §112. In recent years, the landscape of patent law in the United States has undergone a significant shift, with courts adopting a more stringent stance on the criteria of enablement and written description.
Americas
WATCH: Aligning innovation, regulation and IP protection
Innovation in the life sciences industries is deeply intertwined with regulatory compliance and intellectual property protection. There is a complex interplay between IP and regulatory laws, creating unique challenges for lawyers working in this field. Join us as the panel discusses the delicate balance between innovation, regulatory requirements and safeguarding IP.